Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06018311
Other study ID # STUDY00003138
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 28, 2023
Est. completion date February 28, 2025

Study information

Verified date September 2023
Source University of Arizona
Contact Rachel E Jarrett, MPH
Phone 520-626-0375
Email UACC-IIT@uacc.arizona.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the feasibility and effects of an adapted Exercising Together, a partnered resistance training program, on the physical and mental health of prostate cancer survivors and their informal caregiver. The Exercising Together program is designed to promote teamwork during supervised group exercise classes delivered remotely through videoconferencing software. The intervention period will be 3-months with a 3-month follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date February 28, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria (Survivor only): 1. Self-identifies as Hispanic 2. Histologically confirmed prostate cancer diagnosis (self-report) 3. Completed primary treatment at least 6 weeks prior at time of enrollment 4. Has an identified caregiver in any relationship role (e.g., spouse, sibling, parent, friend) who can participate with them. Inclusion Criteria (Caregivers): 1. Identifies as an individual (e.g., family member or friend) who provides unpaid care or support to a participating prostate cancer survivor. Inclusion Criteria (Survivors and Caregivers): 1. =18 years of age 2. Understands (ability to read and speak) English or Spanish and able to provide informed consent 3. Meets the American College of Sports Medicine pre-participation screening criteria for exercise 4. Ability to ambulate (with or without assistive devices) 5. Willing to attend study group exercise classes online, complete remote assessments, and answer online surveys 6. Has access to a mobile device with camera and internet. 7. Able to participate in classes at same time as other participating member. Exclusion Criteria: 1. Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing informed consent as determined by the professional opinion of the Principal Investigator 2. A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate intensity exercise or poses a significant safety concern/risk for the well-being of the participant (e.g., declared pregnancy, poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, severe hearing or vision impairment) 3. Knowingly unable to attend >75% of the intervention classes due to conflict with the designated time of day, days of the week, and/or location for the exercise class which they initially enrolled 4. Incapable of providing informed consent, answering survey questions, participating in the intervention, and following directions during performance testing when English or Spanish language is used 5. Unable to be in the same location with participating member during remote exercise classes and performance testing and/or insufficient internet connectivity to support required videoconferencing software

Study Design


Intervention

Behavioral:
Exercising together
The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.

Locations

Country Name City State
United States University of Arizona Cancer Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability measured by adherence to intervention Acceptability will be measured by adherence to the intervention calculated as the total number of classes attended divided by the total possible schedule the patient could attend using descriptive statistics. 3 months
Primary Appropriateness measured by retention rate Will be determined as the retention rate- calculated as the number of dyads completing the study versus consented using descriptive statistics. 3 months
Primary Feasibility measured by enrollment rate Will be determined as the enrollment rate- the number of dyads enrolled out of those approached and eligible using descriptive statistics. 3 months
Primary Implementation Success - composite measure of acceptability, appropriateness, and feasibility. Implementation success is a composite measure that will be measured by a single questionnaire that will determine the extent to which the intervention is considered acceptable, appropriate, and feasible. The single questionnaire will consist of 3 measures that will be summed into one final score, The Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). Responses from AIM, IAM, and FIM are summary scored with a possible range of 12-60; higher scores indicate greater acceptability, appropriateness, and feasibility. 3 months
Secondary Physical activity Moderate to vigourous physical activity and sedentary time estimated using Rapid Assessment of Physical Activity (RAPA) Physical activity will be measured over a 6 month period. It will be measured at baseline, 3 months, and 6 months.
Secondary Health-Related Quality of Life (HR-QOL) for the caregiver Measured by the 27 item Functional Assessment of Cancer Therapy - General (FACT-G), which includes subscales on physical, social, emotional, and functional well-being. FACT-G is 27 items while FACT-P is 39 items. Response items are five-point Likert scales, where higher scores indicate higher HR-QOL. HR-QOL will be measured over a 6 month period. It will be measured at baseline, 3 months, and 6 months.
Secondary Health-Related Quality of Life (HR-QOL) for the survivor Measured by the 39 item Functional Assessment of Cancer Therapy - Prostate (FACT-P), which includes subscales on physical, social, emotional, and functional well-being and an additional subscale specific to prostate cancer. Response items are five-point Likert scales, where higher scores indicate higher HR-QOL.physical, social, emotional, and functional well-being. FACT-G is 27 items while FACT-P is 39 items. FACT-P includes an additional subscale specific to prostate cancer. Response items are five-point likert scales, where higher scores indicate higher HR-QOL. HR-QOL will be measured over a 6 month period. It will be measured at baseline, 3 months, and 6 months.
Secondary Relationship Health Measured by the Relationship Quality Index (RQI), a six-item assessment of communication and satisfaction on a five-point likert scale. Relationship Health will be measured over a 6 month period. It will be measured at baseline, 3 months, and 6 months.
Secondary Objective Physical Function Measured by the Short Physical Performance Battery (SPPB) to determine ability to perform tasks of daily living independently. The SPPB includes 3 timed tests: 5 repeated chair stands, standing balance, and gait speed over 4 meters. The possible range of scores is 0-12. Objective Physical Function will be measured over a 6 month period. It will be measured at baseline, 3 months, and 6 months.
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A